Principal Scientist, Immunology

If you are unable to complete this application due to a disability, contact this employer to ask for an accommodation or an alternative application process.

Full Time Employee 06-Assoc Director Frederick, MD, US

30+ days ago Requisition

Salary Range: $ To $ Annually

Tonix is a fully integrated biotechnology company, publicly traded on NASDAQ (ticker: TNXP), with marketed products and a pipeline of development candidates. The Company is focused on commercializing, developing, discovering, and licensing therapeutics to treat and prevent human disease. In August 2025, Tonix received FDA approval for Tonmya™ (cyclobenzaprine HCl sublingual tablets), a first-in-class, once‑daily, non‑opioid treatment for fibromyalgia. Tonmya is the first new fibromyalgia therapy approved in over 15 years, following successful Phase 3 trials demonstrating significant symptom improvement.

Commercial launch is expected in the fourth quarter of 2025. Tonix also markets Zembrace® Sym Touch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg, both indicated for the treatment of acute migraine with or without aura in adults.

Tonix’s development portfolio includes product candidates in central nervous system (CNS), immunology, immuno‑oncology, infectious disease and rare disease. The CNS pipeline features both small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. The infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox, which also serves as a live virus vaccine platform for other infectious diseases.

Finally, rare disease portfolio includes a product in development for Prader‑Willi syndrome, which has both orphan drug designation and rare pediatric disease designation grants from the FDA.

Tonix owns and operates a state‑of‑the‑art infectious disease research facility in Frederick, Md.

Please visit  for specifics on the pipeline.

* All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.

Tonix is seeking a highly motivated and innovative Principal Scientist with a background in immunology, autoimmunity or oncology to contribute to research and development across our growing immunology portfolio. This is an excellent opportunity to directly participate and obtain exposure to the end‑to‑end product development process including early‑stage therapeutic discovery, nonclinical safety and pharmacological evaluation, cGMP manufacturing and clinical evaluation. The candidate will have a Ph.D. or M.D./Ph.D. in a relevant field, a strong publication record, and experience working in an interdisciplinary team environment.

The position is located at the Tonix Research and Development Center (RDC) which is the innovation and development arm of Tonix Pharmaceuticals. The RDC houses state‑of‑the‑art equipment (i.e., high content imaging, mass spectrometry, spectral flow cytometry, multi‑parallel bioreactors, etc.) and is responsible for development of efficient and cutting‑edge treatment methods for various diseases including infectious diseases, oncology, and other indications.

This position will require an in‑depth knowledge of in‑vivo immunology and/or virology; will involve organizing and implementing complex research plans, developing methods of testing, data collection and analysis; and will involve writing reports containing descriptive, analytical, and evaluative content. The duties will also require the exercise of independent discretion and judgment in carrying out research activities within the predetermined research scope.

Experience in the composition of scientific publications, research program technical reports, and research grants is required.

• Establish and maintain a robust flow cytometry pipeline to support in-depth immunology research.
• Conduct independent and original research supporting the Tonix portfolio and RDC mission.
• Develop novel methods and assays to contribute to the RDC research…